company_id,asset_id,asset_name,aliases,stage,therapeutic_area,as_of_date,indication
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,23,(MajesTEC-4),,Registration,Oncology,,Acute Myeloid Leukemia (cAMeLot-
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,14,(ORIGAMI-2),,Registration,Oncology,,Multiple Myeloma CD38 exposed
jnj,71,1-3PLs,1-3PLs; 1-3PLs (MajesTEC-3),Phase 2,Oncology,,autoleucel) Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve (amivantamab) Cancer (ORIGAMI-5) Multiple Myeloma CD38 exposed
jnj,64,Azacitidine,Azacitidine; Azacitidine (cAMeLot-2); Cusatuzumab; JNJ-74494550,Registration,Oncology,,Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG
jnj,64,Azacitidine,Azacitidine; Azacitidine (cAMeLot-2); Cusatuzumab; JNJ-74494550,Registration,Oncology,,Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG
jnj,64,Azacitidine,Azacitidine; Azacitidine (cAMeLot-2); Cusatuzumab; JNJ-74494550,Registration,Oncology,,Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7)
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,9,Bleximenib,Azacitidine; Bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,"Newly Diagnosed AML, with Venetoclax and"
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,31,CAPLYTA,CAPLYTA; CAPLYTA (lumateperone); lumateperone,Phase 1,Neuroscience,,Pediatric Psychiatric
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,3,CARVYKTI (Ciltacabtagene,CARVYKTI (Ciltacabtagene,Phase 1,Oncology,,Frontline Multiple
jnj,29,Colitis,PURSUIT 2,Phase 2,Immunology,,Psoriatic Arthritis
jnj,29,Colitis,PURSUIT 2,Phase 2,Immunology,,Psoriatic Arthritis
jnj,29,Colitis,PURSUIT 2,Phase 2,Immunology,,Psoriatic Arthritis
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,39,Disorder,,Registration,Neuroscience,,with Suicidal Ideation
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,10,ERLEADA,apalutamide; ARN509; CB7630; Darolutamide; Deltasone; Docetaxel; Enzalutamide; ERLEADA; ERLEADA (apalutamide); JNJ-56021927; LHRHa; Placebo; Prednisone; tomography; XTANDI; Zytiga,Phase 3,Oncology,,ASCT Localized Prostate
jnj,59,Gravis,CNTO1959; Deucravacitinib; Golimumab; Gravis; Gravis (Vivacity MG3); Guselkumab; Icotrokinra; JNJ-77242113; JNJ-78934804; JNJ-80202135; JNJ-86507083; M281; Nipocalimab; Placebo; STELARA; TREMFYA; Ustekinumab; Vivacity MG3,Phase 2,Neuroscience,,Indications for Major Depressive Disorder
jnj,59,Gravis,CNTO1959; Deucravacitinib; Golimumab; Gravis; Gravis (Vivacity MG3); Guselkumab; Icotrokinra; JNJ-77242113; JNJ-78934804; JNJ-80202135; JNJ-86507083; M281; Nipocalimab; Placebo; STELARA; TREMFYA; Ustekinumab; Vivacity MG3,Phase 2,Neuroscience,,Indications for Major Depressive Disorder
jnj,59,Gravis,CNTO1959; Deucravacitinib; Golimumab; Gravis; Gravis (Vivacity MG3); Guselkumab; Icotrokinra; JNJ-77242113; JNJ-78934804; JNJ-80202135; JNJ-86507083; M281; Nipocalimab; Placebo; STELARA; TREMFYA; Ustekinumab; Vivacity MG3,Phase 2,Neuroscience,,Indications for Major Depressive Disorder
jnj,59,Gravis,CNTO1959; Deucravacitinib; Golimumab; Gravis; Gravis (Vivacity MG3); Guselkumab; Icotrokinra; JNJ-77242113; JNJ-78934804; JNJ-80202135; JNJ-86507083; M281; Nipocalimab; Placebo; STELARA; TREMFYA; Ustekinumab; Vivacity MG3,Phase 2,Neuroscience,,Indications for Major Depressive Disorder
jnj,59,Gravis,CNTO1959; Deucravacitinib; Golimumab; Gravis; Gravis (Vivacity MG3); Guselkumab; Icotrokinra; JNJ-77242113; JNJ-78934804; JNJ-80202135; JNJ-86507083; M281; Nipocalimab; Placebo; STELARA; TREMFYA; Ustekinumab; Vivacity MG3,Phase 2,Neuroscience,,Indications for Major Depressive Disorder
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,38,Gravis Pediatrics,VIBRANCE MG,Registration,Neuroscience,,Demyelinating Polyneuropathy
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,30,Hemolytic Anemia,ENERGY,Registration,Immunology,,Alloimmune Thrombocytopenia
jnj,72,INLEXZO,Cetrelimab; Cisplatin; gemcitabine; INLEXZO; INLEXZO (gemcitabine; JNJ-17000139; JNJ-42756493; JNJ-63723283,Phase 3,Oncology,,High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive (SunRISe-3)
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 1,Oncology,,Non Muscle Invasive (SunRISe-3)
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,1,INLEXZO (gemcitabine,INLEXZO (gemcitabine,Phase 3,Oncology,,High Risk High Risk Non Muscle
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 1,Neuroscience,,Alzheimer's Disease-Related
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,33,ITI-1284,,Phase 3,Neuroscience,,with Generalized Anxiety
jnj,35,Indications,,Phase 2,Neuroscience,,for Major Depressive Disorder
jnj,35,Indications,,Phase 2,Neuroscience,,for Major Depressive Disorder
jnj,35,Indications,,Phase 2,Neuroscience,,for Major Depressive Disorder
jnj,65,JNJ-1493,JNJ-1493,Phase 1,Oncology,,Hematological
jnj,65,JNJ-1493,JNJ-1493,Phase 1,Oncology,,Hematological
jnj,65,JNJ-1493,JNJ-1493,Phase 1,Oncology,,Hematological
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy
jnj,60,JNJ-1887 sCD59,JNJ-1887 sCD59,Phase 3,Neuroscience,,Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,15,JNJ-1900,JNJ-1900; JNJ-1900 (NBTXR3); JNJ-90301900; NBTXR3,Phase 1,Oncology,,Lung Cancer
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,20,JNJ-2175,JNJ-2175,Phase 3,Oncology,,Solid Tumors
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,16,JNJ-2761,JNJ-2761,Phase 1,Oncology,,Multiple Myeloma
jnj,66,JNJ-3413,JNJ-3413,Phase 3,Oncology,,Lymphoma
jnj,66,JNJ-3413,JNJ-3413,Phase 3,Oncology,,Lymphoma
jnj,66,JNJ-3413,JNJ-3413,Phase 3,Oncology,,Lymphoma
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,17,JNJ-4680,JNJ-4680,Phase 1,Oncology,,Lung Cancer
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,21,JNJ-4681,JNJ-4681,Phase 3,Oncology,,Hematological Malignancies
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 1,Immunology,,Psoriatic Arthritis nipocalimab​ Systemic Lupus
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease
jnj,28,JNJ-4804 Co-antibody,JNJ-4804 Co-antibody,Phase 3,Immunology,,Crohn's Disease nipocalimab​ Idiopathic Inflammatory
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,58,JNJ-5120,JNJ-5120,Phase 1,Neuroscience,,Major Depressive
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,18,JNJ-5322,JNJ-5322,Phase 1,Oncology,,Multiple Myeloma
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,22,JNJ-7446,JNJ-7446,Phase 3,Oncology,,Lung Cancer
jnj,73,JNJ-8377,JNJ-8377,Phase 1,Oncology,,Lymphoma
jnj,74,JNJ-8543,JNJ-8543,Phase 3,Oncology,,Hematological Malignancies
jnj,62,Leprosy,,Phase 3,,,under review by regulatory bodies.
jnj,62,Leprosy,,Phase 3,,,under review by regulatory bodies.
jnj,62,Leprosy,,Phase 3,,,under review by regulatory bodies.
jnj,44,MorphoSys AG; JNJ-2113: Protagonist Therapeutics;,,Phase 3,,,and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;
jnj,44,MorphoSys AG; JNJ-2113: Protagonist Therapeutics;,,Phase 3,,,and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;
jnj,44,MorphoSys AG; JNJ-2113: Protagonist Therapeutics;,,Phase 3,,,and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;
jnj,54,Myeloma,AQUILA,Phase 2,Oncology,,intravesical delivery
jnj,54,Myeloma,AQUILA,Phase 2,Oncology,,intravesical delivery
jnj,54,Myeloma,AQUILA,Phase 2,Oncology,,intravesical delivery
jnj,70,OARS,OARS,Phase 2,Neuroscience,,Agitation Disorder
jnj,70,OARS,OARS,Phase 2,Neuroscience,,Agitation Disorder
jnj,69,PROTOSTAR,PROTOSTAR,Registration,Immunology,,Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia
jnj,69,PROTOSTAR,PROTOSTAR,Registration,Immunology,,Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia
jnj,75,PulmonaryArterialH,PulmonaryArterialH,Phase 3,,,SIRTUROLeprosyunderreviewbyregulatorybodies.
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Colorectal Cancer
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,Frontline Non Small
jnj,5,RYBREVANT,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; RYBREVANT; RYBREVANT (amivantamab); YH-25448; YH25448,Phase 3,Oncology,,"Frontline Non Small chemotherapy (PAPILLON) Bleximenib Newly Diagnosed AML, with Venetoclax and ERLEADA (apalutamide) ASCT Localized Prostate"
jnj,43,SIRTURO,SIRTURO,Phase 3,,,L e p r o s y under review by regulatory bodies.
jnj,43,SIRTURO,SIRTURO,Phase 3,,,L e p r o s y under review by regulatory bodies.
jnj,43,SIRTURO,SIRTURO,Phase 3,,,L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen
jnj,43,SIRTURO,SIRTURO,Phase 3,,,L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen
jnj,43,SIRTURO,SIRTURO,Phase 3,,,L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,37,SPRAVATO,esketamine; JNJ-54135419; SPRAVATO; SPRAVATO (esketamine),Phase 3,Neuroscience,,Major Depressive Disorder Pediatrics
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,24,STELARA,CNTO1959; Guselkumab; Placebo; STELARA; STELARA (ustekinumab); TREMFYA; ustekinumab,Phase 1,Immunology,,Pediatric Juvenile
jnj,67,Subcutaneous Induction,ASTRO; Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Subcutaneous Induction; Subcutaneous Induction (ASTRO); Velcade,Phase 2,Immunology,,(ICONIC-PsA)
jnj,67,Subcutaneous Induction,ASTRO; Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Subcutaneous Induction; Subcutaneous Induction (ASTRO); Velcade,Phase 2,Immunology,,(ICONIC-PsA)
jnj,67,Subcutaneous Induction,ASTRO; Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Subcutaneous Induction; Subcutaneous Induction (ASTRO); Velcade,Phase 2,Immunology,,(ICONIC-PsA)
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory (MonumenTAL-6)
jnj,12,TALVEY + TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; TALVEY; TALVEY + TECVAYLI; Teclistamab; TECVAYLI; velcade,Phase 3,Oncology,,Relapsed Refractory (MonumenTAL-6)
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Multiple Myeloma
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory (MajesTEC-9)
jnj,2,TECVAYLI,Bortezomib; Daratumumab; Darzalex; Dexamethasone; JNJ-54767414; JNJ-64007957; JNJ-64407564; JNJ-79635322; Lenalidomide; melphalan; Pomalidomide; revlimid; Talquetamab; teclistamab; TECVAYLI; TECVAYLI (teclistamab); velcade,Phase 1,Oncology,,Relapsed Refractory (MajesTEC-9)
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Pediatric Ulcerative
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 1,Immunology,,Ulcerative Colitis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Juvenile Psoriatic
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,25,TREMFYA,CNTO1959; guselkumab; Placebo; TREMFYA; TREMFYA (guselkumab),Phase 3,Immunology,,Pediatric Psoriasis
jnj,42,UCL Business Plc; JNJ-1887: Hemera Biosciences;,,Phase 2,,,and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;
jnj,42,UCL Business Plc; JNJ-1887: Hemera Biosciences;,,Phase 2,,,and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;
jnj,42,UCL Business Plc; JNJ-1887: Hemera Biosciences;,,Phase 2,,,and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n
jnj,61,actorXla,,Phase 2,,,i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson
jnj,61,actorXla,,Phase 2,,,i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson
jnj,61,actorXla,,Phase 2,,,i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson
jnj,63,amivantamab,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; YH-25448; YH25448,Phase 2,Oncology,,Cancer (ORIGAMI-5)
jnj,63,amivantamab,5-fluorouracil; amivantamab; Carboplatin; Cetuximab; Co-Formulated; Erbitux; JNJ-61186372; JNJ-73841937; Lazertinib; Levoleucovorin; Pemetrexed; YH-25448; YH25448,Phase 2,Oncology,,Cancer (ORIGAMI-5)
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve
jnj,55,autoleucel,autoleucel; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone; Fludarabine; JNJ-64407564; JNJ-68284528; Lenalidomide; Talquetamab,Phase 2,Oncology,,Myeloma Transplant Eligible vs intravesical delivery Bladder Cancer BCG-naïve
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,19,bleximenib,Azacitidine; bleximenib; Cusatuzumab; JNJ-74494550; JNJ-75276617; Venetoclax,Phase 3,Oncology,,Relapsed Refractory 1)
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 1,Immunology,,Psoriatic Arthritis
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 3,Immunology,,Crohn's Disease (ICONIC-CD)
jnj,26,icotrokinra,icotrokinra; JNJ-77242113; Placebo,Phase 3,Immunology,,Crohn's Disease (ICONIC-CD)
jnj,7,intravesical delivery,,Phase 2,Oncology,,Bladder Cancer BCG-naïve
jnj,7,intravesical delivery,,Phase 2,Oncology,,Bladder Cancer BCG-naïve
jnj,7,intravesical delivery,,Phase 2,Oncology,,Bladder Cancer BCG-naïve
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,56,intravesical delivery system,,Registration,Oncology,,Invasive Bladder Cancer BCG
jnj,40,milvexian(F,milvexian(F,Phase 1,,,"A t r i a l F i b r i l l a t assets. The pipeline includes assets currently progressing This information is as of January 21, 2026 -milvexian: Bristol Myers Squibb; AAV-RPGR: Company, a subsidiary of Merck & Co., Inc. BTG International; DARZALEX and DARZALEX FASPRO: Duobody Platform bispecific antibody programs:"
jnj,40,milvexian(F,milvexian(F,Phase 1,,,"A t r i a l F i b r i l l a t assets. The pipeline includes assets currently progressing This information is as of January 21, 2026 -milvexian: Bristol Myers Squibb; AAV-RPGR: Company, a subsidiary of Merck & Co., Inc. BTG International; DARZALEX and DARZALEX FASPRO: Duobody Platform bispecific antibody programs:"
jnj,40,milvexian(F,milvexian(F,Phase 1,,,"A t r i a l F i b r i l l a t assets. The pipeline includes assets currently progressing This information is as of January 21, 2026 -milvexian: Bristol Myers Squibb; AAV-RPGR: Company, a subsidiary of Merck & Co., Inc. BTG International; DARZALEX and DARZALEX FASPRO: Duobody Platform bispecific antibody programs:"
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 1,Immunology,,Hemolytic Disease
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Fetal and Neonatal
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Immunology,,Warm Autoimmune
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,57,nipocalimab,JNJ-80202135; JNJ-86507083; M281; nipocalimab; Placebo,Phase 3,Neuroscience,,Chronic Inflammatory
jnj,68,of the Fetus and Newborn,AZALEA; of the Fetus and Newborn; of the Fetus and Newborn (AZALEA),Phase 2,Immunology,,Colitis (QUASAR JR)
jnj,68,of the Fetus and Newborn,AZALEA; of the Fetus and Newborn; of the Fetus and Newborn (AZALEA),Phase 2,Immunology,,Colitis (QUASAR JR)
jnj,68,of the Fetus and Newborn,AZALEA; of the Fetus and Newborn; of the Fetus and Newborn (AZALEA),Phase 2,Immunology,,Colitis (QUASAR JR) Therapy
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,4,pasritamig,JNJ-78278343; pasritamig,Phase 1,Oncology,,Prostate Cancer
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,32,seltorexant,seltorexant,Phase 1,Neuroscience,,Adjunctive Treatment Insomnia Symptoms
jnj,45,ypertension75mg,UNISUS; ypertension75mg; ypertension75mg(UNISUS),Registration,,,"pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor"
jnj,45,ypertension75mg,UNISUS; ypertension75mg; ypertension75mg(UNISUS),Registration,,,"pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor"
jnj,45,ypertension75mg,UNISUS; ypertension75mg; ypertension75mg(UNISUS),Registration,,,"pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor"
